[Granulocyte transfusion as a part of compensation for a biological defect]

As compared to the widespread application of erythrocyte- and platelet transfusion, granulocyte substitution is still not without difficulties. In spite of the introduction of automated separation systems, the procurement of adequate numbers of granulocytes is not easy, mainly for numerical-technical reasons. Also, the need for an effective organizational background and a close functional connection of transfusion medicine and oncology are not appropriately observed. Whereas the results of studies investigating the prophylactic value of granulocyte transfusions remained negative, mainly due to an inadequate granulocyte dosage, the importance of earlier trials, demonstrating the therapeutic efficacy remains without objection, as subsequent studies also suffer from the transfusion of cells too low for clinical requirements. Granulocyte substitution is only one aspect of the biological defect compensation in the immunocompromised host. In spite of a reduced frequency of applications and the introduction of newer therapeutic developments, granulocyte transfusion, if sufficient cell numbers are applied, may well play a valuable role within the concept of biological defect compensation for the control of septicemia.